제네릭 의약품 시장 규모, 점유율과 동향 분석 보고서 : 유형별, 용도별, 제품별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2026-2033년)

Generic Pharmaceuticals Market Summary

The global generic pharmaceuticals market size was estimated at USD 454.7 billion in 2025 and is projected to reach USD 770.0 billion by 2033, growing at a CAGR of 6.5% from 2026 to 2033. The growth can be attributed to the constant increase in the number of ANDA approvals and generic drug product launches.

The generic pharmaceuticals industry is a critical pillar of modern healthcare, enabling access to therapeutically equivalent alternatives to originator drugs following patent expiry. Generics are approved through abbreviated regulatory pathways (such as ANDA in the U.S.), which prioritize bioequivalence, safety, and quality while enabling faster market entry and supporting healthcare cost containment. In 2025, competitive dynamics remained driven by patent expirations and associated legal challenges. For example, litigation surrounding the generic version of Novartis' heart failure drug Entresto led to a temporary pause on U.S. generic entry, underscoring how intellectual property disputes can materially influence launch timing despite patent expiry expectations.

Manufacturers remained focused on portfolio expansion and regulatory execution. Alembic Pharmaceuticals secured multiple U.S. FDA approvals in 2025 across cardiovascular, oncology, ophthalmic, and dermatology products, highlighting ongoing diversification beyond commoditized oral solids and increasing emphasis on complex and specialty generics. Regulatory scrutiny remained a defining operational factor. Glenmark Pharmaceuticals received U.S. FDA warning letters regarding manufacturing practices in 2025, underscoring the importance of compliance discipline and quality assurance for sustained access to regulated markets.

Looking ahead, upcoming patent cliffs in high-value therapies continued to shape strategic positioning. The anticipated patent expiry of semaglutide was widely viewed as a significant future opportunity for generic manufacturers, particularly in India and other emerging markets, reflecting growing interest in metabolic and chronic disease segments. Overall, in 2025, the generic pharmaceuticals industry remained highly competitive and regulation-driven, balancing patent-linked entry opportunities, compliance requirements, pricing pressure, and supply reliability as manufacturers adapt to evolving therapeutic and policy environments.

Global Generic Pharmaceuticals Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global generic pharmaceuticals market report based on type, application, product, route of administration, distribution channel, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Simple Generics
• Specialty Generics
• Biosimilars
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Central Nervous System Disorders
• Respiratory Diseases
• Hormones and Related Diseases
• Gastrointestinal Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Cancer
• Diabetes
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule
• Large Molecule
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Inhalable
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Product
  • 1.2.4. Route of Administration
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Generic Pharmaceuticals Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Generic Pharmaceuticals Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Simple Generics
  • 4.4.1. Simple Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Specialty Generics
  • 4.5.1. Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Biosimilars
  • 4.6.1. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Generic Pharmaceuticals Market: Application Business Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Central Nervous System Disorders
  • 5.4.1. Central Nervous System Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Respiratory Diseases
  • 5.5.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Hormones and Related Diseases
  • 5.6.1. Hormones and Related Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Gastrointestinal Diseases
  • 5.7.1. Gastrointestinal Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Cardiovascular Diseases
  • 5.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Infectious Diseases
  • 5.9.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Cancer
  • 5.10.1. Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Diabetes
  • 5.11.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.12. Others
  • 5.12.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Generic Pharmaceuticals Market: Product Business Analysis

• 6.1. Product Market Share, 2025 & 2033
• 6.2. Product Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 6.4. Small Molecule
  • 6.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Large Molecule
  • 6.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Generic Pharmaceuticals Market: Route of Administration Business Analysis

• 7.1. Route of Administration Market Share, 2025 & 2033
• 7.2. Route of Administration Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 7.4. Oral
  • 7.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Injectable
  • 7.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Inhalable
  • 7.6.1. Inhalable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Generic Pharmaceuticals Market: Distribution Channel Business Analysis

• 8.1. Distribution Channel Market Share, 2025 & 2033
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 8.4. Online Pharmacies
  • 8.4.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Hospital Pharmacies
  • 8.6.1. Hospital Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Generic Pharmaceuticals Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. North America Generic Pharmaceuticals Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Type Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. U.S. Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Type Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. Canada Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Type Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. Mexico Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Type Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. UK Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Type Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Germany Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Type Disease Prevalence
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Reimbursement Framework
    • 9.5.4.5. France Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Type Disease Prevalence
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Reimbursement Framework
    • 9.5.5.5. Italy Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Type Disease Prevalence
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Reimbursement Framework
    • 9.5.6.5. Spain Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Type Disease Prevalence
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Reimbursement Framework
    • 9.5.7.5. Denmark Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Type Disease Prevalence
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Reimbursement Framework
    • 9.5.8.5. Sweden Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Type Disease Prevalence
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Reimbursement Framework
    • 9.5.9.5. Norway Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Type Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. Japan Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Type Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. China Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Type Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. India Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Type Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Australia Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Type Disease Prevalence
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. Reimbursement Framework
    • 9.6.6.5. South Korea Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Type Disease Prevalence
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Reimbursement Framework
    • 9.6.7.5. Thailand Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Type Disease Prevalence
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Framework
    • 9.7.2.5. Brazil Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Type Disease Prevalence
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Framework
    • 9.7.3.5. Argentina Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Type Disease Prevalence
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Framework
    • 9.8.2.5. South Africa Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Type Disease Prevalence
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Framework
    • 9.8.3.5. Saudi Arabia Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Type Disease Prevalence
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Framework
    • 9.8.4.5. UAE Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Type Disease Prevalence
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Framework
    • 9.8.5.5. Kuwait Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Teva Pharmaceutical Industries
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Type Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Sandoz
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Type Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Sun Pharmaceutical Industries
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Type Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Viatris
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Type Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Dr. Reddy's Laboratories
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Type Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Cipla
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Type Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Aurobindo Pharma
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Type Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Lupin
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Type Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Glenmark Pharmaceuticals
    • 10.5.9.1. Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Type Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Torrent Pharmaceuticals
    • 10.5.10.1. Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Type Benchmarking
    • 10.5.10.4. Strategic Initiatives